There's no money in vaccines - yeah, right!

[Guest guest]

Reuters News

July 22, 2008

Wyeth profit falls 7 percent, but beats estimates

NEW YORK (Reuters) - Wyeth (WYE.N: Quote, Profile, Research, Stock Buzz) on

Wednesday said second-quarter earnings fell 7 percent, hurt by generic forms

of its Protonix ulcer drug, although results beat estimates as they were

helped by its vaccine for childhood infections and a drug for inflammatory

disease.

Wyeth said it earned $1.12 billion, or 83 cents per share, compared with

$1.2 billion, or 87 cents per share, in the year-earlier period.

Excluding special items, Wyeth earned 91 cents per share, 4 cents ahead of

the average estimate of analysts, according to Reuters Estimates.

Revenue rose 5 percent to $5.95